Press releases

2019  |  2018  |  All
October 24, 2019
Compass Therapeutics to Present Preclinical Data on a Novel PD-1/PD-L1 Bispecific Antibody and from its Proprietary Innate Cell Engager Platform at the 2019 SITC Meeting
October 22, 2019
Compass Therapeutics Appoints Leading Immuno-Oncology Researchers to Its Immuno-Oncology Scientific Advisory Board
August 1, 2019
Compass Therapeutics Appoints Julie Sunderland to Board of Directors

Presentations and publications

View all
November 12, 2019 | SITC 2019
CTX-8371, a Novel Bispecific Targeting both PD-1 and PD-L1, is more Potent than Combination anti-PD-1 and PD-L1 Therapy and Provides Enhanced Protection from Tumors in vivo
November 12, 2019 | SITC 2019
A novel class of Innate Cell Engagers targeting NKp30
April 10, 2019 | Keystone Symposia Conference: “D2: Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies”
Novel class of NK engagers targeting NKp30 selected from unbiased screen of common light chain based bispecific antibodies

In the news

View all
October 2, 2018
FierceBiotech’s 2018 Fierce 15
July 13, 2018
Compass Therapeutics raises $130 million to develop I-O candidate
July 12, 2018
Compass Therapeutics eyes possible IPO after $132M investment

Events

2019 ACR/ARP Annual Meeting
November 8 – 13
Atlanta, Georgia
PEGS Europe 2019
November 18 – 22
Lisbon, Portugal
61st ASH Annual Meeting & Exposition
December 7 – 10
Orlando, FL